Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Cyclo Therapeutics

December 7, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through

Continue reading

November 18, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

April 29, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

April 22, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

February 11, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021

Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and

Continue reading

January 8, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C

Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo

Continue reading

December 10, 2020 CD as API / Events / Pharma applications

Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering

Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin

Continue reading

October 19, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA

Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick

Continue reading

September 9, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial

Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)

Continue reading

June 21, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient

Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C

Continue reading

Posts navigation

1 2 Next Posts»

Recent Posts

  • Recent books on cyclodextrins
  • β-cyclodextrin complexes with propolis and royal jelly components
  • HPBCD in an approved non-replicating adenoviral vector-based gene therapy product
  • Methyl BCD alters cell envelop studied by AFM
  • Patent application: gamma-cyclodextrin-based polymer for prevention or treatment of cholesterol metabolism-related diseases

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (206)
  • CD derivatives (257)
  • Cosmetics and toilettry (21)
  • Drug delivery (437)
  • E-ducation (54)
  • Environmental (77)
  • Events (160)
  • Food (124)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (15)
  • Non-pharma applications (215)
  • Other industrial use (59)
  • Pharma applications (703)
  • Supramolecular systems (25)
  • Uncategorized (43)

Top Posts

  • Recent books on cyclodextrins
  • Lanosterol eye drops for cataract treatment
  • 7th European Cyclodextrin Conference
  • β-cyclodextrin complexes with propolis and royal jelly components
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • Website of EuroCD Conference is open
  • How air fresheners work?
  • HPBCD in an approved non-replicating adenoviral vector-based gene therapy product
  • Methyl BCD alters cell envelop studied by AFM
  • International Symposium of Drug Delivery Systems (SDDS-2022)

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 524 other subscribers
 

Loading Comments...